Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056696 | 0.78 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL803827 | 0.74 | MTNR1A (0.41) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL25732142 | 0.74 | LMNA (0.42) | MTNR1A | |
| SCHEMBL4347797 | 0.73 | MTNR1A (0.43) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28357714 | 0.73 | MTNR1A (0.43) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL13615626 | 0.73 | MTNR1A (0.43) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12394472 | 0.71 | MTNR1A (0.40) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL27866082 | 0.70 | PBRM1 (0.32) | — | |
| SCHEMBL4688545 | 0.70 | MTNR1B (0.39) | MTNR1AMTNR1BHTR2AHTR2CHTR2B | |
| SCHEMBL338470 | 0.70 | MTNR1B (0.39) | MTNR1AMTNR1BHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116856183-A | Method for manufacturing antibacterial and antiviral synthetic leather | 苏州丰欣新材料科技有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-113402490-B | Preparation method of 1,2,6, 7-tetrahydro-8H-indeno [5,4-b ] furan-8-one | 白银京宇新药业有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-113861113-A | Preparation and application of fused ring pyridine compound and derivative thereof | 中国科学院福建物质结构研究所 | 2021-12-31 | — | — | CN | claimed |
| CN-113402490-A | Preparation method of 1,2,6, 7-tetrahydro-8H-indeno [5,4-b ] furan-8-one | 白银京宇新药业有限公司 | 2021-09-17 | — | — | CN | claimed |
| CN-113045524-A | Synthesis method of ramelteon intermediate | 河南牧业经济学院 | 2021-06-29 | — | — | CN | claimed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | claimed |
| US-20130079397-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-28 | — | — | US | claimed |
| EP-2537842-A1 | Crystals of (S)-N-[2-(2,6,7,8-Tetrahydro-1H-indeno[5,4-b]furan-8-yl)ethyl]propionamide | Takeda Pharmaceutical Company Limited (JP) | 2012-12-26 | — | — | EP | claimed |
| US-20120088826-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | claimed |
| WO-2012035303-A2 | A NOVEL PROCESS FOR SYNTHESIS OF RAMELTEON, AND KEY INTERMEDIATES FOR THE SYNTHESIS OF RAMELTEON | CIPLA LIMITED ET AL (IN) | 2012-03-22 | — | — | WO | claimed |
| WO-2011027319-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR RAMELTEON | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | claimed |
| WO-2010041271-A2 | PROCESS FOR PREPARATION OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO[5,4-B]FURAN-8-YL)ETHYL] PROPIONAMIDE AND NOVEL INTERMEDIATES THEREOF | USV LIMITED (IN) | 2010-04-15 | — | — | WO | claimed |
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-05 | — | — | US | claimed |
| EP-1792899-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | claimed |
| CN-115894143-B | Palladium catalyzed double ligand unguided preparation method for deuterated aromatic compound | 宁波萃英化学技术有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-116856183-A | Method for manufacturing antibacterial and antiviral synthetic leather | 苏州丰欣新材料科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023122754-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING GB13, GB22 AND HIMGALINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885HTR2A 26/4885 |
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885HTR2A 26/4885 |
| US-20120088826-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885HTR2A 26/4885 |
| US-20130079397-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885HTR2A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.